Actinium Pharmaceuticals, Inc. (ATNM)

NYSEAMERICAN: ATNM · IEX Real-Time Price · USD
6.94
+0.57 (8.95%)
Feb 20, 2024, 4:00 PM EST - Market closed
8.95%
Market Cap 192.68M
Revenue (ttm) n/a
Net Income (ttm) -50.14M
Shares Out 27.76M
EPS (ttm) -1.93
PE Ratio n/a
Forward PE 6.84
Dividend n/a
Ex-Dividend Date n/a
Volume 304,100
Open 6.34
Previous Close 6.37
Day's Range 6.27 - 6.97
52-Week Range 4.00 - 14.70
Beta -0.12
Analysts Strong Buy
Price Target 25.87 (+272.77%)
Earnings Date Apr 1, 2024

About ATNM

Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and precli... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 49
Stock Exchange NYSEAMERICAN
Ticker Symbol ATNM
Full Company Profile

Financial Performance

In 2022, ATNM's revenue was $1.03 million, a decrease of -9.97% compared to the previous year's $1.14 million. Losses were -$33.02 million, 33.3% more than in 2021.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for ATNM stock is "Strong Buy." The 12-month stock price forecast is $25.87, which is an increase of 272.77% from the latest price.

Price Target
$25.87
(272.77% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

NorthStar Medical Radioisotopes and Alpha-9 Oncology Enter Strategic Long-term Agreement for Supply of Actinium-225 (Ac-225)

BELOIT, Wis. & VANCOUVER, British Columbia--(BUSINESS WIRE)--NorthStar Medical Radioisotopes and Alpha-9 Oncology Enter Strategic Long-term Agreement for Supply of Actinium-225.

6 weeks ago - Business Wire

NorthStar Medical Radioisotopes and Curadh MTR Enter Strategic Collaboration Agreement for Development and Production of Actinium-225 (Ac-225)-based Therapeutic Radiopharmaceuticals for Treatment of Primary and Metastatic Solid Tumors

BELOIT, Wis. & CHESTER SPRINGS, Pa.--(BUSINESS WIRE)--NorthStar Medical Radioisotopes and Curadh MTR Enter Strategic Collaboration Agreement.

6 weeks ago - Business Wire

Actinium Announces Acceptance of Five Abstracts for Presentation at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®

-       Two oral presentations and three poster presentations will highlight Iomab-B and Iomab-ACT CD45 targeted conditioning for bone marrow transplant and CAR-T cellular therapy NEW YORK , Jan. 2, 2...

7 weeks ago - PRNewsWire

Actinium Announces Iomab-B Produces High Response Rates and Significant Improvement in Overall Survival in Relapsed Refractory AML Patients with Active Disease Overcoming TP53 Mutation

Relapsed or refractory AML patients with TP53 mutation known to have dismal outcomes due to limited effective treatment options Median Overall Survival of 5.49 months observed in patients with a TP53 ...

2 months ago - PRNewsWire

Actinium's Four Presentations at ASH Highlight the Positive Outcomes for Iomab-B and Actimab-A in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Oral presentation highlighted Iomab-B improves overall survival in patients with TP53 mutation with active, relapsed or refractory AML Eighth oral presentation of the Phase 3 SIERRA results at ASH con...

2 months ago - PRNewsWire

Actinium to Highlight Broad Potential of Targeted Radiotherapies Iomab-B and Actimab-A for Relapsed or Refractory and Elderly Acute Myeloid Leukemia Patients at the 65th ASH Annual Meeting & Exposition

Oral presentation to highlight Iomab-B's ability to significantly improve overall survival in patients with relapsed or refractory AML with a TP53 mutation Four presentations in total demonstrating th...

2 months ago - PRNewsWire

Actinium Presents Preclinical Data at SITC Demonstrating Actimab-A's Potential to Restore T Cell Immunity in the Solid Tumor Microenvironment Supporting Immunotherapy Combinations

Actimab-A can target CD33 positive immune suppressing myeloid derived suppressor cells and restore T cell proliferation and effector response Solid tumor MDSC infiltration and uptake of Actimab-A conf...

3 months ago - PRNewsWire

Actinium Appoints Lynn Bodarky as Chief Business Officer

-       Senior leader with proven track record of executing business development and licensing transactions totaling $5 billion at multinational pharmaceutical and biotechnology companies NEW YORK , N...

3 months ago - PRNewsWire

Actinium Pharmaceuticals to Attend Bio-Europe Munich 2023

NEW YORK , Nov. 2, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that it ...

3 months ago - PRNewsWire

Actinium Announces Oral Presentation at ASH Annual Meeting Highlighting Iomab-B Treatment Significantly Increased Median Overall Survival in Relapsed or Refractory AML Patients with Highly Unfavorable TP53 Gene Mutation in the Phase 3 SIERRA Trial

-      Relapsed or refractory AML patients with a TP53 mutation receiving Iomab-B led allogeneic bone marrow transplant had a median Overall Survival of 5.49 months compared to 1.66 months in patients...

3 months ago - PRNewsWire

Actinium Announces NIH Grant Extension to Advance Clinical Development of Next-Generation CD45 Targeted Conditioning Agent Iomab-ACT with Memorial Sloan Kettering's CAR-T Cell Therapy

- Ongoing clinical trial is the first ever to combine targeted radiotherapy conditioning, Iomab-ACT, with CAR-T cell therapy to achieve lymphodepletion along with reduction of cytokine release syndrom...

4 months ago - PRNewsWire

Actinium Pharma Highlights Abstract Accepted for Poster Presentation at the SITC 38th Annual Meeting

NEW YORK , Sept. 27, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today details an abstr...

5 months ago - PRNewsWire

Actinium Pharma Presents Survival Data from Extended Follow-Up from Actimab-A + CLAG-M Trial and Preclinical Data Supporting Program Expansion with FLT3 Inhibitor Combinations at SOHO

- Extended follow-up in the Actimab-A + CLAG-M trial showed median overall survival in patients proceeding to bone marrow transplant of 24 months in all patients and 30 months in patients who received...

5 months ago - PRNewsWire

Actinium Pharma Highlights Three Abstracts Accepted for Poster Presentation at the SOHO 2023 Annual Meeting

-       First ever data demonstrating anti-leukemic effect of Actimab-A in FLT3 Mutant AML models NEW YORK , Aug. 31, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actiniu...

6 months ago - PRNewsWire

NorthStar Medical Radioisotopes and Curadh MTR Announce a Strategic Long Term Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)

BELOIT, Wis. & CHESTER SPRINGS, Pa.--(BUSINESS WIRE)--NorthStar Medical Radioisotopes and Curadh MTR sign a strategic long term supply agreement for n.c.a. therapeutic radioisotope actinium-225 (Ac-22...

6 months ago - Business Wire

Actinium Pharma Highlights Abstracts Accepted for Oral and Poster Presentation at the EANM 2023 Congress

NEW YORK, Aug. 21, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today details two abstra...

6 months ago - PRNewsWire

Actinium Pharma to Present at the 2nd Annual Targeted Radiopharmaceuticals Summit

NEW YORK , July 24, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that th...

7 months ago - PRNewsWire

NorthStar Medical Radioisotopes Announces Supply Agreement with Nucleus RadioPharma for Alpha-emitting Therapeutic Radioisotope Actinium-225 (Ac-225)

BELOIT, Wis. & ROCHESTER, Minn.--(BUSINESS WIRE)--NorthStar Medical Radioisotopes and Nucleus RadioPharma sign a supply agreement for alpha-emitting therapeutic radioisotope actinium-225 (Ac-225).

8 months ago - Business Wire

SNMMI 2023 Annual Meeting Abstract of the Year Awarded to Actinium's Iomab-B Phase 3 SIERRA Data

- SNMMI Henry N. Wagner, Jr., Abstract of the Year award represents top selection out of more than 1,500 abstracts accepted for presentation NEW YORK , June 26, 2023 /PRNewswire/ -- Actinium Pharmaceu...

8 months ago - PRNewsWire

PanTera and TerraPower Isotopes join forces to accelerate access to actinium-225

Strategic collaboration signed to support the development of radiopharmaceuticals in the fight against cancer Chicago, IL, USA, June 26, 2023: TerraPower Isotopes and PanTera, the Belgian joint ventur...

8 months ago - GlobeNewsWire

Actinium Pharma Highlights Six Abstracts Accepted for Oral and Poster Presentation at the SNMMI 2023 Annual Meeting

NEW YORK , June 23, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today details the six a...

8 months ago - PRNewsWire

Actinium Pharma to Present at the Maxim Healthcare Virtual Conference

NEW YORK , June 16, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that th...

8 months ago - PRNewsWire

Actinium Pharma to Present at the TD Cowen Radiopharmaceutical Innovation Summit

NEW YORK , June 14, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that th...

8 months ago - PRNewsWire

Actinium Announces Positive Pivotal Phase 3 SIERRA Trial Results in an Oral Presentation at the EHA 2023 Congress

SIERRA results demonstrate unprecedented bone marrow transplant access and outcomes with Iomab-B BLA filing for Iomab-B expected by year end 2023 based on positive pivotal Phase 3 SIERRA results NEW Y...

9 months ago - PRNewsWire

Actinium Pharma Set to Join Russell 2000® and Russell 3000® Indexes

NEW YORK , June 7, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that it ...

9 months ago - PRNewsWire